{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T09:21:51Z","timestamp":1785835311754,"version":"3.56.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.gene.2022.146881","type":"journal-article","created":{"date-parts":[[2022,9,11]],"date-time":"2022-09-11T05:34:30Z","timestamp":1662874470000},"page":"146881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors"],"prefix":"10.1016","volume":"847","author":[{"given":"Ioannis A.","family":"Voutsadakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.gene.2022.146881_b0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/nrd.2016.253","article-title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","volume":"16","author":"Ashkenazi","year":"2017","journal-title":"Nat Rev Drug Discov"},{"issue":"7391","key":"10.1016\/j.gene.2022.146881_b0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"Barretina","year":"2012","journal-title":"Nature"},{"issue":"7753","key":"10.1016\/j.gene.2022.146881_b0015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41586-019-1103-9","article-title":"Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens","volume":"568","author":"Behan","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.gene.2022.146881_b0020","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.gene.2022.146881_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: A Precision Oncology Knowledge Base","author":"Chakravarty","year":"2017","journal-title":"JCO Precision Oncology"},{"issue":"11","key":"10.1016\/j.gene.2022.146881_b0030","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.2741\/3517","article-title":"Mitochondria, Bcl-2 family proteins and apoptosomes: of worms, flies and men","volume":"14","author":"Colin","year":"2009","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"10265","key":"10.1016\/j.gene.2022.146881_b0035","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.gene.2022.146881_b0040","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2021.12.005","article-title":"Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis","volume":"33","author":"Curigliano","year":"2022","journal-title":"Ann. Oncol."},{"issue":"13","key":"10.1016\/j.gene.2022.146881_b0045","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2009620118","article-title":"Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma","volume":"118","author":"Dalton","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.gene.2022.146881_b0050","first-page":"438","article-title":"Breast cancer statistics, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.gene.2022.146881_b0055","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1042\/BST20210750","article-title":"Targeting the BCL-2-regulated apoptotic pathway for the treatment of solid cancers","volume":"49","author":"Fairlie","year":"2021","journal-title":"Biochem. Soc. Trans."},{"issue":"20","key":"10.1016\/j.gene.2022.146881_b0060","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and Letrozole in Advanced Breast Cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"269","key":"10.1016\/j.gene.2022.146881_b0065","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"issue":"12","key":"10.1016\/j.gene.2022.146881_b0070","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1038\/cdd.2015.73","article-title":"Myeloid cell leukemia-1 is an important apoptotic survival factor in triple-negative breast cancer","volume":"22","author":"Goodwin","year":"2015","journal-title":"Cell Death Differ."},{"issue":"11","key":"10.1016\/j.gene.2022.146881_b0075","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.3390\/cancers13112618","article-title":"Therapeutics Targeting the Core Apoptotic Machinery","volume":"13","author":"Hamilton","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.gene.2022.146881_b0080","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.gene.2022.146881_b0085","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gene.2022.146881_b0090","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/cdd.2017.186","article-title":"BCL-2 family proteins: changing partners in the dance towards death","volume":"25","author":"Kale","year":"2018","journal-title":"Cell Death Differ."},{"issue":"2","key":"10.1016\/j.gene.2022.146881_b0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/febs.13554","article-title":"Inhibitor of apoptosis proteins as intracellular signaling intermediates","volume":"283","author":"Kocab","year":"2016","journal-title":"FEBS J."},{"issue":"15_suppl","key":"10.1016\/j.gene.2022.146881_b0100","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.2017.35.15_suppl.1044","article-title":"Safety and efficacy of the BCL2 inhibitor venetoclax in estrogen receptor (ER) and BCL2-positive metastatic breast cancer: The mBEP study.","volume":"35","author":"Lindeman","year":"2017","journal-title":"JCO"},{"issue":"15_suppl","key":"10.1016\/j.gene.2022.146881_b0105","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1200\/JCO.2021.39.15_suppl.1004","article-title":"Results from VERONICA: A randomized, phase II study of second-\/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA\/MBC).","volume":"39","author":"Lindeman","year":"2021","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.gene.2022.146881_b0110","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1158\/1078-0432.CCR-17-1606","article-title":"Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression","volume":"24","author":"Lochmann","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.gene.2022.146881_b0115","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov"},{"issue":"1\u20132","key":"10.1016\/j.gene.2022.146881_b0120","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.cell.2015.11.062","article-title":"Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance","volume":"164","author":"Marcotte","year":"2016","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.gene.2022.146881_b0125","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1007\/s12094-016-1573-2","article-title":"HER2 mRNA transcript quantitation in breast cancer","volume":"19","author":"Meehan","year":"2017","journal-title":"Clin. Transl. Oncol."},{"issue":"15","key":"10.1016\/j.gene.2022.146881_b0130","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/onc.2015.287","article-title":"Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer","volume":"35","author":"Merino","year":"2016","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.gene.2022.146881_b0135","doi-asserted-by":"crossref","first-page":"jcs212563","DOI":"10.1242\/jcs.212563","article-title":"Re-inforcing the cell death army in the fight against breast cancer","volume":"131","author":"Oudenaarden","year":"2018","journal-title":"J. Cell Sci."},{"issue":"6","key":"10.1016\/j.gene.2022.146881_b0140","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.gene.2022.146881_b0145","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J. Clin."},{"issue":"14","key":"10.1016\/j.gene.2022.146881_b0150","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.gene.2022.146881_b0155","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"9","key":"10.1016\/j.gene.2022.146881_b0160","doi-asserted-by":"crossref","first-page":"4829","DOI":"10.21873\/anticanres.14486","article-title":"The Future of ER+\/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors","volume":"40","author":"Stravodimou","year":"2020","journal-title":"Anticancer Res."},{"issue":"3","key":"10.1016\/j.gene.2022.146881_b0165","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","article-title":"Defining a Cancer Dependency Map","volume":"170","author":"Tsherniak","year":"2017","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.gene.2022.146881_b0170","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood-2018-02-791350","article-title":"The rise of apoptosis: targeting apoptosis in hematologic malignancies","volume":"132","author":"Valentin","year":"2018","journal-title":"Blood"},{"issue":"D1","key":"10.1016\/j.gene.2022.146881_b0175","doi-asserted-by":"crossref","first-page":"D923","DOI":"10.1093\/nar\/gky872","article-title":"Cell Model Passports-a hub for clinical, genetic and functional datasets of preclinical cancer models","volume":"47","author":"van der Meer","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.gene.2022.146881_b0180","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1080\/028418600430707","article-title":"Apoptosis and the pathogenesis of lymphoma","volume":"39","author":"Voutsadakis","year":"2000","journal-title":"Acta Oncol."},{"issue":"11","key":"10.1016\/j.gene.2022.146881_b0185","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.21873\/anticanres.11145","article-title":"Immune Blockade Inhibition in Breast Cancer","volume":"36","author":"Voutsadakis","year":"2016","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.gene.2022.146881_b0190","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40291-019-00420-2","article-title":"Clinical Implications of Chromosomal Instability (CIN) and Kinetochore Abnormalities in Breast Cancers","volume":"23","author":"Voutsadakis","year":"2019","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"10.1016\/j.gene.2022.146881_b0195","doi-asserted-by":"crossref","first-page":"859","DOI":"10.4149\/neo_2019_190309N203","article-title":"Chromosome 17 centromere amplification and chromosomal instability (CIN) in breast cancer: Pathogenic and therapeutic implications","volume":"66","author":"Voutsadakis","year":"2019","journal-title":"Neoplasma"},{"issue":"10","key":"10.1016\/j.gene.2022.146881_b0200","doi-asserted-by":"crossref","first-page":"3079","DOI":"10.3390\/jcm9103079","article-title":"8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy","volume":"9","author":"Voutsadakis","year":"2020","journal-title":"JCM"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007004?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111922007004?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T16:57:20Z","timestamp":1759856240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111922007004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":40,"alternative-id":["S0378111922007004"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2022.146881","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular alterations in anti-apoptotic BCL2 family proteins in breast cancer cell line models, drug sensitivities and dependencies to guide the development of BCL2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2022.146881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"146881"}}